Scholarlink

Background <p>As the predominant and most aggressive subtype of renal cell carcinoma (RCC), clear cell RCC (ccRCC) represents the considerable heterogeneity present across RCC subtypes. Although tertiary lymphoid structures (TLS) are implicated in tumor immunity, their prognostic role and underlying mechanisms in ccRCC remain unclear. Characterizing TLS-associated genes may offer novel insights into disease progression and support improved risk stratification and personalized therapy.</p> Methods <p>The single-cell transcriptome and spatial transcriptome data were utilized to analyze the B-cell infiltration in ccRCC and to screen for differentially expressed genes within TLS of ccRCC. Next, consensus clustering and survival analysis based on Lasso-Cox regression were applied to identify TLS prognostic markers in ccRCC. Subsequently, a prognostic prediction model for ccRCC was established by integrating key clinical characteristics and these prognostic biomarkers. The immunofluorescence experiments were performed on ccRCC clinical specimens to validate the clinical relevance of proteins in candidate biomarkers for ccRCC.</p> Results <p>Aberrant expression of three TLS-associated genes (<i>CEMIP</i>, <i>PLA2G2A</i>, and <i>IGHGP</i>) was associated with poor prognosis in ccRCC, identifying them as potential prognostic biomarkers. Then, the protein-coding biomarkers were validated in ccRCC pathological tissue samples by immunofluorescence. Mechanistically, aberrant expression underlies the functional transition in TLS from anti-tumor immunity to tumor promotion, potentially mediated by dysregulation of oncogenic processes via multi-pathway interactions. A prognostic model based on these biomarkers demonstrated high predictive accuracy.</p> Conclusions <p>Combining single-cell analysis with spatial transcriptomic profiling identifies spatially-resolved functional heterogeneity in ccRCC-associated TLS, demonstrating their context-dependent immunomodulatory roles. Aberrant expression of specific TLS-associated proteins is associated with a functional transition from anti-tumor immunity to tumor promotion. <i>CEMIP</i>, <i>PLA2G2A</i>, and <i>IGHGP</i> may serve as potential prognostic biomarkers; derived models achieve high predictive accuracy, highlighting clinical potential. Immunofluorescence confirmed the enrichment of protein-level biomarkers within TLS in ccRCC clinical specimens. Our findings elucidate TLS-related genes regulating tumor-immune interactions, advancing understanding of ccRCC prognosis and providing tools for prediction and personalized therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Combining spatial and single-cell transcriptome data to analyze tertiary lymphoid structures in clear cell renal cell carcinoma reveals prognostic biomarkers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月15日

查看全文
  • Xuechao Li,
  • Pu Liu,
  • Man Li,
  • Yongzhu Zhou,
  • Tianwei Li,
  • Tao Yang,
  • Jinkai Dong,
  • Chengwei Fu,
  • Yunping Zhu,
  • Lijun Chen,
  • Jie Ma,
  • Wanlin Liu

摘要

Background

As the predominant and most aggressive subtype of renal cell carcinoma (RCC), clear cell RCC (ccRCC) represents the considerable heterogeneity present across RCC subtypes. Although tertiary lymphoid structures (TLS) are implicated in tumor immunity, their prognostic role and underlying mechanisms in ccRCC remain unclear. Characterizing TLS-associated genes may offer novel insights into disease progression and support improved risk stratification and personalized therapy.

Methods

The single-cell transcriptome and spatial transcriptome data were utilized to analyze the B-cell infiltration in ccRCC and to screen for differentially expressed genes within TLS of ccRCC. Next, consensus clustering and survival analysis based on Lasso-Cox regression were applied to identify TLS prognostic markers in ccRCC. Subsequently, a prognostic prediction model for ccRCC was established by integrating key clinical characteristics and these prognostic biomarkers. The immunofluorescence experiments were performed on ccRCC clinical specimens to validate the clinical relevance of proteins in candidate biomarkers for ccRCC.

Results

Aberrant expression of three TLS-associated genes (CEMIP, PLA2G2A, and IGHGP) was associated with poor prognosis in ccRCC, identifying them as potential prognostic biomarkers. Then, the protein-coding biomarkers were validated in ccRCC pathological tissue samples by immunofluorescence. Mechanistically, aberrant expression underlies the functional transition in TLS from anti-tumor immunity to tumor promotion, potentially mediated by dysregulation of oncogenic processes via multi-pathway interactions. A prognostic model based on these biomarkers demonstrated high predictive accuracy.

Conclusions

Combining single-cell analysis with spatial transcriptomic profiling identifies spatially-resolved functional heterogeneity in ccRCC-associated TLS, demonstrating their context-dependent immunomodulatory roles. Aberrant expression of specific TLS-associated proteins is associated with a functional transition from anti-tumor immunity to tumor promotion. CEMIP, PLA2G2A, and IGHGP may serve as potential prognostic biomarkers; derived models achieve high predictive accuracy, highlighting clinical potential. Immunofluorescence confirmed the enrichment of protein-level biomarkers within TLS in ccRCC clinical specimens. Our findings elucidate TLS-related genes regulating tumor-immune interactions, advancing understanding of ccRCC prognosis and providing tools for prediction and personalized therapy.